Drug Testing in Rodent PKD Models
While C. elegans and zebrafish models are very convenient for rapid drug screening, testing of promising therapies in well-characterized, orthologous rodent models of autosomal dominant PKD (ADPKD) and autosomal recessive PKD (ARPKD) is necessary to establish the basis for clinical trials.
To accurately evaluate a potential therapy, the chosen model must demonstrate a consistent disease course (i.e., moderately progressive time course — not too fast, not too slow) that is appropriate for testing an intervention.
Four models exhibit the above characteristics and are used by the core for drug testing:
Depending on the mechanism of action or the intended effect of a particular drug, a number of technologies may be used to measure or determine the outcome of an intervention. The core has available the following methods for evaluating results in rodent models:
Of these methods, histomorphometric analysis and renal function are the most commonly used ways to determine the efficacy of a particular treatment.
© 2013 Mayo Foundation for Medical Education and Research. All rights reserved.